<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="76714">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02106858</url>
  </required_header>
  <id_info>
    <org_study_id>16778</org_study_id>
    <secondary_id>SV1314KR</secondary_id>
    <nct_id>NCT02106858</nct_id>
  </id_info>
  <brief_title>Stivarga Regulatory Post-Marketing Surveillance Study in Korea</brief_title>
  <acronym>StivargaPMS</acronym>
  <official_title>StivargaÂ® Regulatory Post-Marketing Surveillance Study in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate and collect post-marketing data on the safety of Stivarga in real world
      practice in its registered indication(s) as required by Health Authority.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2014</start_date>
  <completion_date type="Anticipated">May 7, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 7, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with serious adverse events</measure>
    <time_frame>Up to 28 days after terminating treatment</time_frame>
    <description>Every 2 months (monthly safety assessment within first two cycles)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with adverse drug reactions (ADRs)</measure>
    <time_frame>Up to 28 days after terminating treatment</time_frame>
    <description>Every 2 months (monthly safety assessment within first two cycles)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3750</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Patients treated by Physician with Stivarga under approved local prescriptions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib (Stivarga,BAY73-4506)</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with metastatic colorectal cancer or metastatic or unresectable locally
        advanced GIST(Gastrointestinal stromal tumors) by physician.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

          -  Patients diagnosed with metastatic colorectal cancer or metastatic or unresectable
             locally advanced GIST(gastrointestinal stromal tumors) by physician.

          -  Patients who are prescribed with Stivarga for the first time.

          -  Exclusion Criteria:

          -  All contra-indications according to the local marketing authorization have to be
             considered.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 13, 2017</lastchanged_date>
  <firstreceived_date>April 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stivarga / Regorafenib / Metastatic Colorectal Cancer / Metastatic or unresectable locally advanced GIST (Gastrointestinal stromal tumors)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
